RecruitMe Clinical Trial

A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma
Study of Pembrolizumab Plus Gemcitabine/Cisplatin as First-Line Therapy in Patients with Biliary Tract Carcinoma
Sponsor:Merck Sharp and Dohme Corp.
Enrolling:Male and Female Patients
Minimum Age:18 years old
IRB Number:AAAS6251
U.S. Government ID:NCT04003636
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information:

The purpose of this study is to determine whether combining the drug pembrolizumab with the standard first-line chemotherapy treatment of gemcitabine and cisplatin for biliary tract carcinoma will more effectively fight your cancer than the standard chemotherapy treatment alone. Pembrolizumab is thought to work by preventing cells within the immune system that fight tumors from dying.

Do You Qualify?
Are you 18 years of age or older?YesNo
Do you have advanced and/or unresectable biliary tract cancer?YesNo
Are you willing to have a tumor biopsy or provide a sample of your tumor tissue?YesNo
Submit
Cancel
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Research Nurse Navigator
Email: cancerclinicaltrials@cumc.columbia.edu
Phone: 212-342-5162